Bayer (OTCPK:BAYRY) (OTCPK:BAYZF) shares traded higher in Germany on Friday after the company lifted its full-year guidance ...

The Food and Drug Administration (FDA) has extended the review period for elinzanetant, an investigational hormone-free therapy for the treatment of moderate to severe vasomotor symptoms (VMS) due to ...

The extended review for Elinzanetant is supported by data from the Phase III OASIS 1, 2, and 3 trials, which supported the ...

FDA delays Bayer’s elinzanetant review to Oct 2025 amid liver safety concerns; global approvals still on track.

Another study linked GLP-1 receptor agonist use with higher odds of developing nonarteritic anterior ischemic optic neuropathy, a potentially blinding eye condition. Last month, the European Medicines ...

Barclays (LON: BARC) views the development as “a small negative for Bayer,” though analysts remain positive on the drug’s ...

US FDA extends review period for Bayer’s NDA for elinzanetant to treat moderate to severe VMS due to menopause: Berlin Monday, July 28, 2025, 16:00 Hrs [IST] Bayer announced tha ...

The government has revealed details of its plans to cut foreign aid, with support for women's health and children's education in Africa facing the biggest reductions. Nuala McGovern gets reaction from ...

Berlin: Bayer has announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug ...

The US Food and Drug Administration (FDA) has notified Bayer that it has extended the review period for the New Drug ...